The IGBA International Trade Committee aims to develop a more competitive business environment for the generic and biosimilar medicines industries around the globe.
Its purpose is to foster the spread of generic and biosimilar medicines worldwide increasing their market penetration through the dismantling of barriers to trade, regulatory harmonization, reduction of costs linked to administrative burdens and red tape, and a fair balance between IPR protection and public health needs. To accomplish this, the generic and biosimilar medicines industries require particular attention and a high level of collaboration and coordination among the different regional Associations and their Member companies.
The IGBA International Trade Committee, by virtue of its global perspective, will develop coordinated strategies for the achievements of such goals.
IGBA Files Recommendations for USTR 2016 Special 301 Review – February 5, 2016
Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement – February 4, 2016
Report: Fostering International Trade in Generic and Biosimilar Medicines – September 2015